Following ASCO showing, Bert Vogelstein’s latest startup launches into recurrent cancer detection
Cancer research luminary Bert Vogelstein is adding to his line of cancer diagnostic companies, following Exact Sciences, Inostics, PGDx and Thrive (which was bought by Exact).
Haystack Oncology is launching out of Catalio Capital Management, where Vogelstein serves as a venture partner as well. It’s starting out with a $56 million Series A, adding to its $10 million in seed funding, which was led by Catalio but also featured research tool manufacturer Bruker, the venture arm of Exact, and Alexandria Venture Investments.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.